Year: 2023

SAN JOSE, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) — Credo Technology Group Holding Ltd (Nasdaq: CRDO) (“Credo”) today announced the pricing of an underwritten public offering of 10,000,000 of its ordinary shares at a price to the public of $17.50 per share. An aggregate of 8,940,000 of the shares are being offered by Credo and 1,060,000 shares are being offered by selling shareholders. The gross proceeds from the offering to Credo, before deducting underwriting discounts and commissions and other offering expenses payable by Credo, are expected to be $156.5 million. The offering is scheduled to close on December 8, 2023, subject to the satisfaction of customary closing conditions. Credo’s ordinary shares are listed on the Nasdaq Global Select Market under the ticker symbol “CRDO”. The underwriters for the offering also have a 30-day...

Vicama AS («Vicama») and Vicama Capital AS (“Vicama Capital”) had on 15 November 2023 entered into a share lending agreement with Prosafe SE (the “Company”) and Pareto Securities AS and SpareBank 1 Markets AS (the “Managers”) for the purposes of facilitating settlement of tradeable shares in the private placement announced on 25 October 2023 (the “Private Placement”). Vicama and Vicama Capital are ultimately controlled by Kjell Christian Ulrichsen. Prior to lending the shares, Vicama and Vicama Capital held 735 685 shares, representing 6.39%. Vicama made 353 205 shares available for lending and Vicama Capital made 364 738 shares available for lending. The shares have now been re-delivered. Simen Flaaten is a Director of the Board of Prosafe and the CEO of Vicama Capital. Vicama Capital is defined by the Market Abuse Regulation as a related...

Announcing the successful completion of a joint demonstrator for fail-operational architecture QUEBEC CITY, Canada and VIENNA, Austria, Dec. 06, 2023 (GLOBE NEWSWIRE) — LeddarTech®, an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD and TTTech Auto, a technology leader in automotive safety software, are pleased to announce the completion of a joint demonstrator for a fail-operational architecture based on LeddarTech’s LeddarVision™ software and TTTech Auto’s Safety Co-Pilot solution. TTTech Auto’s innovative Safety Co-Pilot solution tackles the challenges of a safety architecture suitable for autonomous driving on SAE Level 3 and beyond. It is based on a doer channel, which is responsible for the main driving task, and an independent...

Vancouver, British Columbia, Dec. 05, 2023 (GLOBE NEWSWIRE) — Spey Resources Corp. (CSE: SPEY) (OTC: SPEYF) (FRA: 2JS) (“Spey” or the “Company“) announces that it has acquired ownership and control of 1,500,000 common shares (the “Subject Shares”) of First Responder Technologies Inc. (the “Company”). The Subject Shares represented approximately 14.8% of all issued and outstanding common shares of the Company as of September 28, 2023, immediately following the transaction described above, resulting in a corresponding increase in the percentage of shares held by Spey as a result of the transaction. Prior to the transaction described above, Spey held no common shares of the Company. The Subject Shares were acquired through a share transfer agreement made between the Company, Spey and Rauni Malhi (“Malhi”), pursuant...

NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. (NYSE: PFE) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) as well as plans to expand the vepdegestrant development program. Investor Call & Webcast DetailsArvinas will host a conference call and webcast on Wednesday, December 6 at 7:30 a.m. ET to discuss these updates. Participants are invited to listen by going to the Events and Presentation section under the Investors page on the Arvinas website at www.arvinas.com. A replay of the webcast will be archived on the Arvinas...

WATERTOWN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock are being sold by EyePoint. The closing of the offering is expected to occur on or about December 8, 2023, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an...

GUADALAJARA, Mexico, Dec. 05, 2023 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for November 2023, compared with the same period of 2022. For November 2023, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 0.4%, compared to the same period in 2022. Los Cabos and Puerto Vallarta presented an increase in passenger traffic of 4.3% and 3.7%, respectively, compared to November 2022. On the other hand, Montego Bay presented an increase in passenger traffic of 7.3% compared to the same period of 2022.       Domestic Terminal Passengers (in thousands):                                          Airport Nov-22 Nov-23 % Change Jan – Nov 22 Jan – Nov 23 %...

Ad hoc announcement pursuant to Art. 53 LRApproval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels ≥ 2 g/dL (82.3% vs. 0%) and hemoglobin level ≥ 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment1,2  Fabhalta, now available for both previously treated and treatment-naïve patients, is the only FDA-approved Factor B inhibitor of the immune system’s complement pathway, which drives complement-mediated hemolysis in PNH1,6Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients...

IX Acquisition Corp. (NASDAQ: IXAQ) (the “Company”), a blank check company incorporated as a Cayman Islands exempted company, today announced that it has filed a supplement (“Supplement”) to its definitive proxy statement (the “Proxy Statement”) with the US Securities and Exchange Commission (the “SEC”) on November 24, 2023, in connection with an extraordinary general meeting in lieu of an annual general meeting of the shareholders (“Meeting”) to consider and vote on certain proposals, including an extension of the date by which the Company has to complete a business combination from December 12, 2023 on a monthly basis up to ten (10) times until October 12, 2024 (the “Second Extension”). The Supplement provides that the monthly loan amount that IX Acquisition Sponsor LLC (the “Sponsor”) will contribute to the Company’s trust account if...